Session

H. pylori (Posters)

IMPACT OF HELICOBACTER PYLORI INFECTION ON SEVERITY OF METABOLIC SYNDROME-RELATED NONALCOHOLIC FATTY LIVER DISEASE
IMPACT OF HELICOBACTER PYLORI INFECTION ON SEVERITY OF METABOLIC SYNDROME-RELATED NONALCOHOLIC FATTY LIVER DISEASE

H. pylori (Posters)  et al.

EFFICACY AND SAFETY OF MODIFIED BISMUTH QUADRUPLE THERAPY AND CONCOMITANT THERAPY FOR HELICOBACTER PYLORI INFECTION IN RAJAVITHI HOSPITAL: A RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MODIFIED BISMUTH QUADRUPLE THERAPY AND CONCOMITANT THERAPY FOR HELICOBACTER PYLORI INFECTION IN RAJAVITHI HOSPITAL: A RANDOMIZED CONTROLLED TRIAL

H. pylori (Posters)  et al.

RANDOMIZED CLINICAL TRIAL COMPARING TRIPLE THERAPY VERSUS NON-BISMUTH BASED QUADRUPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN KUWAIT
RANDOMIZED CLINICAL TRIAL COMPARING TRIPLE THERAPY VERSUS NON-BISMUTH BASED QUADRUPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN KUWAIT

H. pylori (Posters)  et al.

RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

H. pylori (Posters)  et al.

PCAB-BASED HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH PENICILLIN ALLERGY
PCAB-BASED HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH PENICILLIN ALLERGY

H. pylori (Posters)  et al.

“TEST-AND-TREAT” STRATEGY WITH UREA BREATH TEST: A COST-EFFECTIVE APPROACH FOR THE MANAGEMENT OF HELICOBACTER PYLORI-RELATED DYSPEPSIA AND THE PREVENTION OF PEPTIC ULCER IN THE UNITED KINGDOM-RESULTS OF THE HP-BREATH INITIATIVE
“TEST-AND-TREAT” STRATEGY WITH UREA BREATH TEST: A COST-EFFECTIVE APPROACH FOR THE MANAGEMENT OF HELICOBACTER PYLORI-RELATED DYSPEPSIA AND THE PREVENTION OF PEPTIC ULCER IN THE UNITED KINGDOM-RESULTS OF THE HP-BREATH INITIATIVE

H. pylori (Posters)  et al.

PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF VONOPRAZAN 20 MG VERSUS LANSOPRAZOLE 30 MG IN THE TREATMENT OF ENDOSCOPICALLY CONFIRMED DUODENAL ULCERS IN ASIAN SUBJECTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION
PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF VONOPRAZAN 20 MG VERSUS LANSOPRAZOLE 30 MG IN THE TREATMENT OF ENDOSCOPICALLY CONFIRMED DUODENAL ULCERS IN ASIAN SUBJECTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION

H. pylori (Posters)  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS

H. pylori (Posters)  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

H. pylori (Posters)  et al.

FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

PREVALENCE OF HELICOBACTER PYLORI DECREASED SIGNIFICANTLY DURING THE LAST 25 YEARS AMONG LITHUANIAN MEDICAL STUDENTS
PREVALENCE OF HELICOBACTER PYLORI DECREASED SIGNIFICANTLY DURING THE LAST 25 YEARS AMONG LITHUANIAN MEDICAL STUDENTS

H. pylori (Posters)  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori (Posters)  et al.

Item 21 - 36 / 36
1
2